DelveInsight has launched a new report on “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Prostate Cancer Market Report:
- Iin EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with around 394,000 cases in 2020, followed by France and Italy.
Request for a sample report @ Prostate Cancer Market Outlook 2032.
Key benefits of the report:
- Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer Epidemiology and Prostate Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Prostate Cancer market report provides insights on the current and emerging therapies.
- Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prostate Cancer market.
Got queries? Click here to know more about the Prostate Cancer Market Landscape.
Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide.
Prostate Cancer Market
The dynamics of the Prostate Cancer market are AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp & Dohme, anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2019-2032.
Learn more by requesting for sample @ Prostate Cancer Market Landscape
Prostate Cancer Pipeline Therapies and Key Companies
- Lynparza :AstraZeneca/Merck Sharp & Dohme
- Opdivo: Bristol-Myers Squibb
- Lutathera: Novartis
- Relugolix: Myovant Sciences
- Niraparib: Janssen Research & Development
- HC-1119: Hinova Pharmaceuticals USA
- Ipatasertib: Hoffmann-La Roche
- Talazoparib: Pfizer/Astellas Pharma
- Rucaparib: Clovis Oncology
- ProstAtak: Advantagene or Candel Therapeutics
- Keytruda: Merck Sharp & Dohme
Prostate Cancer Market Drivers
- Increasing Use of Biomarker Testing
- Rising Geriatric Population and High Prevalence Rate of Prostate Cancer
- The surge in Awareness Regarding the Treatment of Prostate Cancer
- Increase in Demand for Prostate Cancer
- Treatment Products
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Prostate Cancer Patient Share (%) Overview at a Glance
5. Prostate Cancer Market Overview at a Glance
6. Prostate Cancer Disease Background and Overview
7. Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Prostate Cancer
9. Prostate Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Prostate Cancer Emerging Therapies
12. Prostate Cancer Market Outlook
13. Country-Wise Prostate Cancer Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/